Saturday, February 18, 2006

Clalit Health Services will pay for Oncotype DX

Jerusalem Post, February 15, 2006
Clalit Health Services will pay $4,000 to test every woman member with breast cancer who is suited to the Oncotype DX genetic test to determine whether their genetic profile gives them the potential to benefit from special chemotherapy. The largest health fund said that it expects between 250 and 300 Clalit members who meet its criteria will require and want such testing, in which a tissue sample removed in surgery is sent abroad. The test has not been included in the Health Ministry's basket of health services, although it was previously a candidate and rejected. Clalit director-general Zev Vurmbrand called the voluntary decision "a breakthrough and good news for women with breast cancer." "We prefer to spend our resources on other proven lifesaving technologies for breast cancer such as Herceptin," a spokesman said. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */